PharmaEssentia

6446.TW

21.12 USD

0.53

+2.57%

Overview

Last close

21.12 usd

Market cap

7.20B usd

52 week high

24.69 usd

52 week low

13.51 usd

Target price

23.7 usd

Valuation

P/E

47.535

Forward P/E

N/A

Price/Sales

15.3357

Price/Book Value

7.812

Enterprise Value

7.14B usd

EV/Revenue

14.5784

EV/EBITDA

42.1541

Key financials

Revenue TTM

489.50M usd

Gross Profit TTM

436.77M usd

EBITDA TTM

158.47M usd

Earnings per Share

0.43 usd

Dividend

0.03 usd

Total assets

1.19B usd

Net debt

-696.45M usd

About

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.